May 2021

The Government of HP in exercise of the powers conferred under article 162 read with proviso of Article 309 of the Constitution of India constituted the HR Staff Selection Commission with its headquarters at Hamirpur vide notification No. Per (APB) B (1 >-1/98 dated 6th October 1998. The commission has been entrusted with the responsibility of making recommendations to all class-ill services/posts including such posts on contract basis under the HP Govt.

The National Centre for Cell Science is an autonomous institution of Department of Biotechnology, Ministry of Science and Technology, Government of India, for a mandate of basic research, teaching & training, and as a national repository for cell lines/hybridomas etc. The centre is located in the midst of academically enriched environment of University of Savitribai Phule Pune Campus, Pune. NCCS invites applications for following posts on various extramural projects purely on temporary basis.

IICB Institute was established in 1935 as the first non official centre in India for biomedical research and was included within the aegis of CSIR in 1956. IICB today is engaged in research on diseases of national importance and biological problems of global interest, employing sophisticated state-of-the-art technology in keeping with the rapid and unprecedented momentum that life science research has gained globally over the last 50 years.

National Institute for Research in Reproductive Health formerly known as Institute for Research in Reproduction is a premier research institute of the Indian Council of Medical Research (ICMR). It is situated in the vicinity of a number of hospitals and research institutes in central Mumbai. Since its inception in 1970, it has been making vigorous efforts to improve the reproductive health of people through research, education and health care services.

Bioclinica is utilizing data and technology to enable more efficient trial conduct. We are looking at ways to reduce the size of the trials, provide greater clarity into the effect of the drug, and to reduce the amount of complexity in the trial. We do this by improving trial design and utilizing advanced analytics to identify patients who would be high responders for a particular clinical trial.

Post : Drug Safety Scientist I

Himalaya began its journey at a time when herbal products were regarded with skepticism. But, our founder persevered to follow his dreams. Pawning his mother's bangles, he bought a hand-operated tableting machine.

Moderna, Inc a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced that the Ministry of Health, Labour and Welfare (MHLW) of Japan granted special approval under article 14-3 of the Pharmaceuticals and Medical Devices Act for emergency use of Moderna’s mRNA COVID-19 vaccine, now known as COVID-19 Vaccine Moderna Intramuscular Injection, in Japan. Distribution by Takeda in Japan will begin immediately.

Pfizer Inc. announced a new agreement with the European Commission (EC) to supply 900 million doses of COMIRNATY, the companies COVID-19 vaccine, to the European Union (EU), with an option for the EC to request up to an additional 900 million doses.

Takeda Pharmaceutical Company Limited announced updated data from the Phase 1/2 trial of mobocertinib (TAK-788) orally administered in patients with epidermal growth factor receptor (EGFR) Exon20 insertion mutation-positive (insertion+) metastatic non-small cell lung cancer (mNSCLC) who received prior platinum-based chemotherapy. The results showed mobocertinib continued to demonstrate clinically meaningful benefit after over a year of follow up and will be presented at the virtual 57th American Society of Clinical Oncology (ASCO) Annual Meeting on June 4.